Skip to main content

Table 4 Sensitivity analyses of the association between high-sensitivity C-reactive protein (hsCRP) and incidence of conduction disorders

From: Elevated high-sensitivity C-reactive protein levels increase the risk of new-onset cardiac conduction disorders

 

Cases/Total

Incidence/1000-person years

Model 1

HR (95% CI)

Model 2

HR (95%CI)

Model 3

HR (95%CI)

Model 4

HR (95%CI)

Regrouping of hsCRP

 Any Cardiac conduction disorder

  hsCRP < 1 mg/L

1800/48180

3.48 (3.33–3.65)

Reference

Reference

Reference

Reference

  hsCRP ≥ 1 mg/L

1814/38054

4.58 (4.38–4.81)

1.26 (1.18–1.34)

1.22 (1.14–1.30)

1.21 (1.13–1.29)

1.19 (1.11–1.27)

 Any Atrioventricular Block

  hsCRP < 1 mg/L

511/48180

0.99 (0.91–1.08)

Reference

Reference

Reference

Reference

  hsCRP ≥ 1 mg/L

610/38054

1.54 (1.43–1.67)

1.49 (1.32–1.67)

1.38 (1.22–1.56)

1.37 (1.21–1.54)

1.33 (1.17–1.50)

 Any Bundle- branch Block

  hsCRP < 1 mg/L

1307/48180

2.53 (2.39–2.67)

Reference

Reference

Reference

Reference

  hsCRP ≥ 1 mg/L

1229/38054

3.11 (2.94–3.29)

1.17 (1.08–1.27)

1.15 (1.06–1.25)

1.14 (1.05–1.24)

1.13 (1.05–1.23)

 Any Left Bundle- branch Block

  hsCRP < 1 mg/L

523/48180

1.01 (0.93–1.10)

Reference

Reference

Reference

Reference

  hsCRP ≥ 1 mg/L

462/38054

1.17 (1.07–1.28)

1.08 (0.95–1.22)

1.03 (0.91–1.17)

1.03 (0.90–1.17)

1.02 (0.90–1.17)

 Right Bundle- branch Block

  hsCRP < 1 mg/L

877/48180

1.69 (1.59–1.81)

Reference

Reference

Reference

Reference

  hsCRP ≥ 1 mg/L

863/38054

2.18 (2.04–2.33)

1.24 (1.12–1.36)

1.24 (1.12–1.36)

1.22 (1.11–1.34)

1.21 (1.09–1.33)

Excluding hsCRP > 10 mg/L at baseline (N = 3342)

 Any Cardiac conduction disorder

  hsCRP ≤ 3 mg/L

2674/70002

3.59 (3.46–3.74)

Reference

Reference

Reference

Reference

  hsCRP > 3 mg/L

758/12890

5.66 (5.27–6.08)

1.44 (1.33–1.57)

1.44 (1.33–1.56)

1.43 (1.32–1.55)

1.41 (1.30–1.53)

  log (hsCRP)/SD

3432/82892

3.91 (3.78–4.04)

1.18 (1.14–1.23)

1.16 (1.12–1.21)

1.15 (1.11–1.20)

1.14 (1.10–1.19)

 Any Atrioventricular Block

  hsCRP ≤ 3 mg/L

781/70002

1.05 (0.98–1.13)

Reference

Reference

Reference

Reference

  hsCRP > 3 mg/L

274/12890

2.05 (1.82–2.30)

1.75 (1.52–2.02)

1.71 (1.49–1.97)

1.70 (1.47–1.96)

1.66 (1.44–1.92)

  log (hsCRP)/SD

1055/82892

1.20 (1.13–1.28)

1.32 (1.23–1.41)

1.27 (1.18–1.36)

1.26 (1.17–1.36)

1.25 (1.16–1.34)

 Any Bundle- branch Block

  hsCRP ≤ 3 mg/L

1921/70002

2.58 (2.47–2.70)

Reference

Reference

Reference

Reference

  hsCRP > 3 mg/L

495/12890

3.69 (3.38–4.04)

1.32 (1.19–1.46)

1.33 (1.20–1.47)

1.32 (1.19–1.46)

1.31 (1.18–1.45)

  log (hsCRP)/SD

2416/82892

2.75 (2.64–2.86)

1.13 (1.08–1.18)

1.12 (1.07–1.17)

1.11 (1.06–1.16)

1.10 (1.05–1.15)

 Any Left Bundle- branch Block

  hsCRP ≤ 3 mg/L

744/70002

1.00 (0.93–1.07)

Reference

Reference

Reference

Reference

  hsCRP > 3 mg/L

194/12890

1.45 (1.26–1.67)

1.32 (1.12–1.55)

1.28 (1.09–1.51)

1.28 (1.09–1.51)

1.27 (1.08–1.50)

  log (hsCRP)/SD

938/82892

1.07 (1.00–1.14)

1.08 (1.00–1.16)

1.05 (0.97–1.12)

1.04 (0.97–1.12)

1.04 (0.97–1.12)

 Right Bundle- branch Block

  hsCRP ≤ 3 mg/L

1320/70002

1.77 (1.68–1.87)

Reference

Reference

Reference

Reference

  hsCRP > 3 mg/L

339/12890

2.53 (2.27–2.81)

1.32 (1.17–1.48)

1.36 (1.20–1.54)

1.34 (1.19–1.52)

1.33 (1.17–1.50)

  log (hsCRP)/SD

1659/82892

1.89 (1.80–1.98)

1.16 (1.10–1.23)

1.16 (1.10–1.23)

1.15 (1.09–1.22)

1.14 (1.08–1.21)

Excluding Myocardial Infarction at baseline (N = 965)

 Any Cardiac conduction disorder

  hsCRP ≤ 3 mg/L

2629/69270

3.56 (3.43–3.70)

Reference

Reference

Reference

Reference

  hsCRP > 3 mg/L

919/15999

5.54 (5.19–5.19)

1.43 (1.32–1.54)

1.43 (1.32–1.54)

1.42 (1.31–1.53)

1.39 (1.29–1.51)

log (hsCRP)/SD

3548/85269

3.93 (3.80–4.06)

1.17 (1.13–1.21)

1.15 (1.11–1.19)

1.15 (1.11–1.18)

1.14 (1.10–1.18)

Any Atrioventricular Block

  hsCRP ≤ 3 mg/L

770/69270

1.04 (0.97–1.12)

Reference

Reference

Reference

Reference

  hsCRP > 3 mg/L

332/15999

2.00 (1.79–2.23)

1.73 (1.52–1.97)

1.69 (1.48–1.93)

1.68 (1.47–1.92)

1.63 (1.43–1.87)

  log (hsCRP)/SD

1102/85269

1.22 (1.15–1.29)

1.28 (1.21–1.37)

1.25 (1.17–1.33)

1.24 (1.17–1.32)

1.22 (1.15–1.30)

 Any Bundle- branch Block

  hsCRP ≤ 3 mg/L

1887/69270

2.56 (2.45–2.68)

Reference

Reference

Reference

Reference

  hsCRP > 3 mg/L

601/15999

3.62 (3.34–3.92)

1.31 (1.18–1.43)

1.32 (1.20–1.45)

1.31 (1.19–1.44)

1.30 (1.18–1.43)

  log (hsCRP)/SD

2488/85269

2.75 (2.65–2.86)

1.12 (1.01–1.17)

1.11 (1.07–1.16)

1.11 (1.06–1.15)

1.10 (1.06–1.15)

 Any Left Bundle- branch Block

  hsCRP ≤ 3 mg/L

734/69270

0.99 (0.93–1.07)

Reference

Reference

Reference

Reference

  hsCRP > 3 mg/L

231/15999

1.39 (1.23–1.58)

1.27 (1.09–1.48)

1.23 (1.05–1.43)

1.23 (1.06–1.44)

1.22 (1.05–1.43)

  log (hsCRP)/SD

965/85269

1.97 (1.00–1.14)

1.07 (1.00–1.14)

1.04 (0.97–1.11)

1.04 (0.97–1.11)

1.03 (0.96–1.11)

 Right Bundle- branch Block

  hsCRP ≤ 3 mg/L

1295/69270

1.75 (1.66–1.86)

Reference

Reference

Reference

Reference

  hsCRP > 3 mg/L

414/15999

2.49 (2.27–2.75)

1.31 (1.17–1.46)

1.36 (1.21–1.52)

1.34 (1.19–1.51)

1.33 (1.18–1.49)

  log (hsCRP)/SD

1709/85269

1.89 (1.81–1.98)

1.15 (1.09–1.21)

1.15 (1.10–1.21)

1.15 (1.09–1.20)

1.14 (1.01–1.20)

  1. Model 1: Corrected for age and gender
  2. Model 2: Corrected for baseline body mass index, physical activity, smoking, alcohol consumption, cholesterol, uric acid, estimated glomerular filtration rate, hypertension, diabetes mellitus, and myocardial infarction based on model 1
  3. Model 3: Corrected for new-onset hypertension, diabetes mellitus, and myocardial infarction during the follow-up based on model 2
  4. Model 4: Corrected for those taking antihypertensive, lipid-lowering, and glucose-lowering drugs at baseline or during the follow-up based on model 3
  5. HR, hazard ratio; Log (hsCRP)/SD, log-transformed for each standard deviation increase in hsCRP; CI, confidence interval